A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

"SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

15mos–17yrs: 1 dose; if previously vaccinated with ≥1 dose of a lower valency pneumococcal conjugate vaccine, then at least 8wks should elapse before receiving Prevnar 20. For intramuscular ...

The Centers for Disease Control and Prevention (CDC) now recommends that American adults over the age of 50 receive the pneumococcal conjugate vaccine, or PCV. The report with the updated ...

Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell ca ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...